SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

Energy Transfer is capturing significant investor attention as the accelerating demand for power in AI data centers highlights the critical importance of its extensive natural gas infrastructure. The community is actively discussing the company's favorable policy developments, ongoing expansion projects, and long-term cash flow security while maintaining a high dividend yield.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is drawing investor attention as community members debate its potential as a 'pipeline-in-a-product' candidate, driven by its selective ITK inhibitor, soquelitinib. While the community is actively discussing ongoing clinical trials, the impact of recent institutional stake updates, and potential acquisition interest, others remain skeptical about the stock's long-term performance given the highly competitive immunology sector.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending due to heightened scrutiny following unverified U.S. government concerns regarding potential export control violations related to its advanced lithography equipment reaching China. While the community is actively debating the credibility of these claims and the potential for regulatory impact, many traders view any associated price weakness as a buying opportunity given the company's entrenched market position and massive backlog.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is seeing heightened market attention as it gains traction as critical infrastructure for institutional finance, particularly through its CCIP technology and role in tokenization. The community remains polarized, with many investors debating whether current price levels represent a significant accumulation opportunity or a sign of stagnant performance.

Goodyear Tire & Rubber Co. engages in the development, manufacture, distribution, and sale of tires. It operates through the following geographical segments: Americas, Europe, Middle East, and Africa, and Asia Pacific. The Americas segment is involved in the development, manufacture, distribution, and sale of tires and related products and services in North, Central, and South America. The Europe, Middle East, and Africa segment focuses on the development, manufacture, distribution, and sale of tires for automobiles, trucks, buses, aircraft, motorcycles, earthmoving, mining, and industrial equipment throughout Europe, the Middle East, and Africa. The Asia Pacific segment refers to the development, manufacture, distribution, and sales of tires for automobiles, trucks, buses, aircraft, farm, earthmoving, mining, and industrial equipment throughout the Asia Pacific region. The company was founded by Frank A. Seiberling on August 29, 1898 and is headquartered in Akron, OH.

Goodyear Tire & Rubber Co.

Goodyear is trending as the company prepares to supply advanced lunar tires for NASA's Artemis program by 2028, sparking community interest in the stock's long-term potential. Investors are also closely monitoring the company's restructuring efforts and ongoing cost-cutting initiatives as they weigh the stock's recovery prospects.

TokenOS is the world’s most advanced AI-powered Web3 development platform, designed to turn natural language prompts into fully functional, production-ready blockchain applications. From simple tokens and memecoins to complex DeFi protocols, TokenOS automates the creation, deployment, and auditing of smart contracts and dApps with enterprise-grade reliability. By combining advanced language models with blockchain infrastructure, TokenOS removes the barriers of technical expertise, making Web3 development accessible to everyone. With instant deployment, built-in security best practices, and cross-chain support on the roadmap, TokenOS empowers entrepreneurs, developers, and creators to launch tokenized businesses and decentralized applications in seconds.

TokenOS AI

TokenOS AI (TOS) is trending as the community highlights the project's v4 launch and a revenue-sharing model that distributes decentralized GPU compute earnings to node runners and stakers. Investors are focusing on the asset's low market cap and potential supply shock, as over 80% of the circulating supply remains locked in staking pools.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is trending as the community celebrates the company's recent trading update, which reaffirmed full-year guidance and signaled confidence in mitigating geopolitical headwinds. Investors are actively discussing the firm's growth potential in the Small Modular Reactor (SMR) market and its strategic expansion into defense contracts, driving strong bullish sentiment regarding its long-term industrial transformation.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is heavily trending as long-term investors debate whether the project is in a terminal decline or entering a pivotal era of commercial execution and institutional adoption. Community discourse is sharply divided, featuring intense frustration over price performance and leadership communication, contrasted by a vocal group of "baggies" continuing to accumulate in anticipation of regulatory clarity and real-world utility growth.

The Render Network is a leading decentralized GPU compute platform for applications ranging from 3D rendering to machine learning and generative AI.  The network connects node operators looking to monetize their idle GPU compute power with artists and developers looking to scale intensive 3D rendering work and machine learning applications in the cloud. Through a decentralized peer-to-peer network, the Render Network achieves unprecedented levels of scale, speed, and economic efficiency. Facilitated by the Render Network Foundation, the ecosystem empowers artists and developers to build services and applications for the emerging digital economy.

Render Token (SOL)

Render (RENDER) is trending as investors focus on its critical role in the DePIN and decentralized GPU compute sectors, viewing the project as a foundational AI infrastructure play despite recent price volatility. While sentiment is mixed, community members are actively discussing the potential for long-term growth driven by real-world adoption and supply constraints, with many choosing to accumulate during market dips.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is gaining traction as investors speculate on potential M&A activity and the commercial potential of Rezpeg, particularly as competitors face setbacks in the dermatology space. Community members are actively debating the impact of upcoming maintenance data readouts and potential settlement developments with Eli Lilly, with many bullish on the drug's long-term durability as a key differentiator.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Jade Biosciences Stock Trading Lower On Monday?

Jade Biosciences reports Phase 1 JADE101 data showing sustained IgA reductions in IgAN, while analyst addresses ADA concerns and timeline expectations.read more...

Jade Biosciences (NASDAQ:JBIO) Stock Price Down 9.6% - Here's What Happened

Jade Biosciences (NASDAQ:JBIO) Shares Down 9.6% - Here's What Happened...

Jade Biosciences (NASDAQ:JBIO) Sets New 1-Year High - Here's What Happened

Jade Biosciences (NASDAQ:JBIO) Hits New 52-Week High - What's Next...

FY2028 Earnings Forecast for JBIO Issued By HC Wainwright

Jade Biosciences, Inc. (NASDAQ:JBIO - Free Report) - Equities research analysts at HC Wainwright issued their FY2028 EPS estimates for Jade Biosciences in a report issued on Monday, April 27th. HC Wainwright analyst A. He forecasts that the company will post earnings of ($2.17) per share for the yea...

Jade Biosciences, Inc. (NASDAQ:JBIO) Short Interest Update

Jade Biosciences, Inc. (NASDAQ:JBIO - Get Free Report) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totaling 3,061,277 shares, an...

Jade Biosciences (NASDAQ:JBIO) Shares Up 9.7%  - What's Next?

Jade Biosciences (NASDAQ:JBIO) Shares Up 9.7% - Should You Buy...

Jade Biosciences, Inc. (NASDAQ:JBIO - Get Free Report) saw a large decline in short interest in March. As of March 31st, there was short interest totaling 1,251,725 shares, a decline of 18.5% from...

Jade Biosciences (NASDAQ:JBIO) Stock Price Up 9.7% - Should You Buy?

Jade Biosciences (NASDAQ:JBIO) Stock Price Up 9.7% - Here's What Happened...

Jade Biosciences (NASDAQ:JBIO) Rating Increased to Hold at Zacks Research

Zacks Research raised Jade Biosciences from a "strong sell" rating to a "hold" rating in a report on Wednesday...

Jade Biosciences (NASDAQ:JBIO) Trading Up 7.9% - What's Next?

Jade Biosciences (NASDAQ:JBIO) Stock Price Up 7.9% - What's Next...

Jade Biosciences, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.

Jade Biosciences Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

JBIOJade Biosciences Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest JBIO News